Every engagement is scoped upfront, quoted at a fixed project fee, and delivered against a clearly defined set of outputs. No hourly meter. No scope creep. No billable-utilisation incentives.
Behind our supplier work sits a proprietary, AI-powered engine — a continuously enriched, multi-source view of the pharma value chain, from APIs and excipients to CDMOs, analytical and contract services and packaging. It screens thousands of manufacturers and suppliers in hours, so a recommendation is grounded in intelligence, not a directory listing. The engine stays in-house; what you receive is the decision.
The right CDMO or supplier — found, vetted and ranked against your criteria: dosage form or modality, certifications, capacity, target markets, timeline.
A ranked shortlist with fit rationale, certifications, geographic fit and risk flags — plus a recommended outreach list.
You're ahead of first GMP, scaling after a raise, or entering a new modality or market.
A category, therapy area or region — mapped, segmented by capability, certification and geography, and read for what it means for your decision.
The competitive landscape with concentration and white-space analysis, and a clear “so what” for a build, buy, partner or entry call.
You're weighing a market decision — or doing diligence on a space.
Intelligence informs every recommendation; a scientist makes the call — sourcing and mapping are scoped and quoted like every Nexaura engagement.
Getting a study off the ground demands trial strategy, the right CRO and vendor partners, and quality and regulatory rigour — at a stage when most teams have no dedicated clinical-operations function. Early choices set the pace, cost and credibility of the whole program.
Most early-stage teams run their first trials without a dedicated clinical-operations function — selecting CROs through founder networks and managing delivery reactively, rather than against a clear operating plan and program-specific criteria.
The path to a clinical-grade product runs through the right CDMO/CMO, sound process and analytical development, and a CMC strategy aligned to your regulatory milestones. Misjudged early, CMC becomes the critical path that holds the whole program back.
CMC is often improvised around whichever manufacturer is easiest to engage, with process, analytics and tech transfer figured out under time pressure. By the time it becomes a regulatory gating item, fixing it costs far more than building it deliberately — and lost development time cannot be recovered.
Supplier selection and qualification, a GxP-ready procurement function, and resilience against single-source and geopolitical exposure — the operational backbone that keeps clinical and commercial supply moving, and the area most likely to surface in diligence.
Programs are advanced on the assumption that critical materials and services will continue to flow at current prices and lead times. That assumption has been tested repeatedly in recent years — and the teams positioned to respond were the ones who had already mapped their exposure and pre-qualified alternatives.
Modern AI and automation are not a separate service — they run through every engagement, applied with judgement rather than hype, to make development, manufacturing and supply-chain operations faster and more reliable.
Most teams know AI should help but lack a grounded way to apply it to regulated drug-development work — separating genuine leverage from noise, and keeping data integrity and quality intact.